2023
Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry
Yazdany J, Ware A, Wallace Z, Bhana S, Grainger R, Hachulla E, Richez C, Cacoub P, Hausmann J, Liew J, Sirotich E, Jacobsohn L, Strangfeld A, Mateus E, Hyrich K, Gossec L, Carmona L, Lawson‐Tovey S, Kearsley‐Fleet L, Schaefer M, Ribeiro S, Al‐Emadi S, Hasseli R, Müller‐Ladner U, Specker C, Schulze‐Koops H, Bernardes M, Fraga V, Rodrigues A, Sparks J, Ljung L, Di Giuseppe D, Tidblad L, Wise L, Duarte‐García A, Ugarte‐Gil M, Colunga‐Pedraza I, Martínez‐Martínez M, Alpizar‐Rodriguez D, Xavier R, Isnardi C, Pera M, Pons‐Estel G, Izadi Z, Gianfrancesco M, Carrara G, Scirè C, Zanetti A, Machado P. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry. Arthritis Care & Research 2023, 76: 274-287. PMID: 37643903, DOI: 10.1002/acr.25220.Peer-Reviewed Original ResearchB-cell depleting therapySevere COVID-19Rheumatic diseasesCOVID-19 outcomesUnvaccinated peopleRisk factorsWorse outcomesCOVID-19Severe COVID-19 outcomesTumor necrosis factor inhibitorsHigh disease activityNecrosis factor inhibitorsConnective tissue diseaseCOVID-19 severityCOVID-19 vaccineThird of individualsLogistic regression modelsCOVID-19 diagnosisOrdinal logistic regression modelsLow HDI regionsMore comorbiditiesUnvaccinated patientsDisease activityUnvaccinated individualsFactor inhibitors
2022
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S, Jacobsohn L, Ja C, Hyrich K, Gossec L, Strangfeld A, Carmona L, Schäfer M, Frãzao-Mateus E, Bulina I, Stafford F, Tufan A, Graver C, Yardımcı G, Zepa J, Al Emadi S, Cook C, Abutiban F, Dey D, Katigbak G, Kaufman L, Kowalski E, Martínez-Martínez M, Patel N, Reyes-Cordero G, Salido E, Smith E, Snow D, Sparks J, Wise L, Bhana S, Gore-Massy M, Grainger R, Hausmann J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open 2022, 8: e002187. PMID: 35387864, PMCID: PMC8987210, DOI: 10.1136/rmdopen-2021-002187.Peer-Reviewed Original ResearchConceptsB-cell depleting therapyBreakthrough infectionsRheumatic diseasesSARS-CoV-2Clinical characteristicsSARS-CoV-2 breakthrough infectionsPre-existing lung diseaseSARS-CoV-2 infectionBreakthrough COVID-19Cell-depleting therapyTwo-dose seriesTime of vaccinationSecond vaccine doseHigh-risk populationMessenger RNA vaccinesCOVID-19 symptomsSingle-dose vaccineCOVID-19Vaccination seriesSystemic glucocorticoidsVaccine doseVaccine effectivenessSecond doseVaccinated individualsLung disease